Accelus vs Amgen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Accelus is a global leader in expandable interbody spinal implant technology with 32,000+ cages implanted in 25 countries; secured new equity financing in May 2025 led by Concord Health Partners;
About
Accelus is a medical device company specializing in expandable interbody spinal implant technology. Its products include bi-directional expandable cages designed to address height, lordosis, and weight parameters during spinal fusion surgery, providing the structural stability of monolithic implants while enabling minimally invasive delivery. With more than 32,000 cages implanted across 25 countries, Accelus has established a strong international commercial presence in the spine surgery market.
Amgen (AMGN) reported $33.4B revenue in FY2024, up 19% YoY (post-Horizon acquisition). Top-5 global biotech. 10+ blockbuster drugs. ~24,000 employees. HQ: Thousand Oaks, CA. Market cap ~$130B.
About
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologics and brought landmark medicines including Epogen, Neupogen, and Enbrel to market. The company reported revenues of $33.4B in FY2024, up 19% year-over-year, boosted by the transformational $28B acquisition of Horizon Therapeutics in October 2023.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.